Emerging drugs in migraine treatment

Expert Opinion on Emerging Drugs

Volumn 8, Issue 2, 2003, Pages 437-456

  Waeber, Christian ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cortical spreading depression; Meninges; Migraine headache; Trigeminal ganglion

Indexed keywords

ACEBUTOLOL; ACETYLSALICYLIC ACID; ALPRENOLOL; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANTIMIGRAINE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARABERSAT; CLOMIPRAMINE; DONITRIPTAN; DOXEPIN; ESTRADIOL; FLUNARIZINE; FLUOXETINE; IS 159; KETOPROFEN; KT2 962; MEFENAMIC ACID; NAPROXEN; NAPROXEN PLUS SUMATRIPTAN; NIMODIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; OXPRENOLOL; PAROXETINE; PINDOLOL; PROPRANOLOL; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SPD 421; TRAZODONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL;

ANALGESIC NEPHROPATHY; APPETITE DISORDER; BRADYCARDIA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DIARRHEA; DIZZINESS; DRUG CONTRAINDICATION; DRUG MECHANISM; DYSPEPSIA; EDEMA; FATIGUE; GASTRITIS; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPOTENSION; MEMORY DISORDER; MIGRAINE; NAUSEA; PHOTOSENSITIVITY DISORDER; PROPHYLAXIS; REVIEW; SEDATION; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; TACHYCARDIA; URINE RETENTION; VIVID DREAM; XEROSTOMIA;

ADRENERGIC BETA-ANTAGONISTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CLINICAL TRIALS; HUMANS; MIGRAINE DISORDERS; MONOAMINE OXIDASE INHIBITORS; SEROTONIN ANTAGONISTS;

EID: 0347627792     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.8.2.437     Document Type: Review

References (198)

1. LIPTON RB, STEWART WF, DIAMOND S, DIAMOND ML, REED M: Prevalence and burden of migraine in the US: data from the American Migraine Study II. Headache (2001) 41(7):646-657.
2. SOLOMON GD, LITAKER DG: The impact of drug therapy on quality of life in headache and migraine. Pharmacoeconomics (1997) 11:334-342.
3. HU XH, MARKSON LE, LIPTON RB, STEWART WF, BERGER ML: Burden of migraine in the United States: disability and economic costs. Arch. Intern. Med. (1999) 159(8):813-818.
4. AURORA SK, AHMAD BK, WELCH KM, BHARDHWAJ P, RAMADAN NM: Transcranial magnetic stimulation confirms hyperexcitability of occipital cortex in migraine. Neurology (1998) 50(4):1111-1114. Human study suggesting that cortical hyperexcitability is associated with migraine pathogenesis.
5. REUTER U, BOLAY H, JANSEN-OLESEN I et al: Delayed inflammation in rat meninges: implications for migraine pathophysiology. Brain (2001) 124(Pt 12):2490-2502. Animal study suggesting that migraine attacks could be caused by oxidative stress leading to delayed inflammation in meninges.
6. TEPPER SJ, MILLSON D: Safety profile of the triptans. Expert Opin. Drug Saf. (2003) 2(2):123-132.
7. REUTER U, SANCHEZ DEL RIO M, MOSKOWITZ MA: Experimental models of migraine. Funct. Neurol. (2000) 15(Suppl. 3):9-18.
8. 1 receptor agonists devoid of vasoconstrictive efficacy can be effective migraine-aborting agents.
9. 1D receptors: pharmacology and therapeutic potential. Serotonin (1996) 1:19-29.
10. 1F receptors modulate c-fos expression within rat trigeminal nucleus caudalis. Eur. J. Pharmacol. (1999) 369(3):271-277.
11. SCHOENEN J, JACQUY J, LENAERTS M: Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology (1998) 50(2):466-470.
12. RAMADAN NM, SCHULTZ LL, GILKEY SJ: Migraine prophylactic drugs: proof of efficacy, utilization and cost. Cephalalgia (1997) 17(2):73-80.
13. PEROUTKA SJ: The pharmacology of current anti-migraine drugs. Headache (1990) 30(1 Suppl.):5-11.
14. SCHOENEN J, MAERTENS DE NOORDHOUT A, TIMSIT-BERTHIER M, TIMSIT M: Contingent negative variation and efficacy of beta-blocking agents in migraine. Cephalalgia (1986) 6(4):229-233.
15. ADLY C, STRAUMANIS J, CHESSON A: Fluoxetine prophylaxis of migraine. Headache (1992) 32(2):101-104.
16. SAPER JR, SILBERSTEIN SD, LAKE AE 3RD, WINTERS ME: Double-blind trial of fluoxetine: chronic daily headache and migraine. Headache (1994) 34(9):497-502.
17. GOMERSALL JD, STUART A: Amitriptyline in migraine prophylaxis. Changes in pattern of attacks during a controlled clinical trial. J. Neurol. Neurosurg. Psychiatry (1973) 36(4):684-690.
18. COUCH JR, ZIEGLER DK, HASSANEIN RS: Evaluation of amitripryline in migraine prophylaxis. Trans. Am. Neurol. Assoc. (1974) 99:94-98.
19. COUCH JR, ZIEGLER DK, HASSANEIN R: Amitriptyline in the prophylaxis of migraine. Effectiveness and relationship of antimigraine and antidepressant effects. Neurology (1976) 26(2):121-127.
20. 2B receptor antagonists.
21. EISENACH JC, GEBHART GF: Intrathecal amitriptyline acts as an N-methyl-D-aspartate receptor antagonist in the presence of inflammatory hyperalgesia in rats. Anesthesiology (1995) 83(5):1046-1054.
22. 2+ levels in neuronal culture. Eur. J. Pharmacol. (1992) 219(1):53-57.
23. LOUIS P: A double-blind placebo-controlled prophylactic study of flunarizine (Sibelium) in migraine. Headache (1981) 21(6):235-239.
24. MENDENOPOULOS G, MANAFI T, LOGOTHETIS I, BOSTANTJOPOULOU S: Flunarizine in the prevention of classical migraine: a placebo-controlled evaluation. Cephalalgia (1985) 5(1):31-37.
25. SORENSEN PS, HANSEN K, OLESEN J: A placebo-controlled, double-blind, crossover trial of flunarizine in common migraine. Cephalalgia (1986) 6(1):7-14.
26. THOMAS M, BEHARI M, AHUJA GK: Flunarizine in migraine prophylaxis: an Indian trial. Headache (1991) 31(9):613-615.
27. SOLOMON GD, STEEL JG, SPACCAVENTO LJ: Verapamil prophylaxis of migraine. A double-blind, placebo-controlled study. JAMA (1983) 250(18):2500-2502.
28. MARKLEY HG, CHERONIS JC, PIEPHO RW: Verapamil in prophylactic therapy of migraine. Neurology (1984) 34(7):973-976.
29. SOLOMON GD, DIAMOND S, FREITAG FG: Verapamil in migraine prophylaxis: comparison of dosages. Clin. Pharmacol. Ther. (1987) 41:202-207.
30. PETERS T, WILFFERT B, VANHOUTTE PM, VAN ZWIETEN PA: Calcium channels in the brain as targets for the calcium-channel modulators used in the treatment of neurological disorders. J. Cardiovasc. Pharmacol. (1991) 18(Suppl. 8):S1-S5.
31. TODA N, TFELT-HANSEN P: Calcium antagonists. In: The Headaches. Olesen J, Tfelt-Hansen P, Welch K (Ed.), Raven Press, New York (1993):383-390.
32. GREENBERG DA: Calcium channel antagonists and the treatment of migraine. Clin. Neuropharmacol. (1986) 9(4):311-328.
33. MIRANDA HF, PELISSIER T, SIERRALTA F: Analgesic effects of intracerebroventricular administration of calcium channel blockers in mice. Gen. Pharmacol. (1993) 24(1):201-204.
34. O'NEILL BP, MANN JD: Aspirin prophylaxis in migraine. Lancet (1978) 2(8101):1179-1181.
35. STENSRUD P, SJAASTAD O: Clinical trial of a new anti-bradykinin, anti-inflammatory drug, ketoprofen (19.583 r.p.) in migraine prophylaxis. Headache (1974) 14(2):96-100.
36. JOHNSON RH, HORNABROOK RW, LAMBIE DG: Comparison of mefenamic acid and propranolol with placebo in migraine prophylaxis. Acta Neurol. Scand. (1986) 73(5):490-492.
37. LINDEGAARD KF, OVRELID L, SJAASTAD O: Naproxen in the prevention of migraine attacks. A double-blind placebo-controlled cross-over study. Headache (1980) 20(2):96-98.
38. WELCH KM, ELLIS DJ, KEENAN PA: Successful migraine prophylaxis with naproxen sodium. Neurology (1985) 35(9):1304-1310.
39. SANCES G, MARTIGNONI E, FIORONI L et al.: Naproxen sodium in menstrual migraine prophylaxis: a double-blind placebo controlled study. Headache (1990) 30(11):705-709.
40. VON KORFF M, GALER BS, STANG P: Chronic use of symptomatic headache medications. Pain (1995) 62(2):179-186.
41. FROLICH JC: A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes. Trends Pharmacol Sci. (1997) 18(1):30-34.
42. PEDERSEN E, MOLLER CE: Methysergide in migraine prophylaxis. Clin. Pharmacol. Ther. (1966) 7(4):520-526.
43. SPIERINGS EL, MESSINGER HB: Flunarizine versus pizotifen in migraine prophylaxis: a review of comparative studies. Cephalalgia (1988) 8(Suppl. 8):27-30.
44. SOYKA D, FRIELING B: Lisuride for the prevention of migraine. Results of a multicenter study. Fortschr. Med. (1989) 107(35):763-766.
45. RAO BS, DAS DG, TARAKNATH VR, SARMA Y: A double blind controlled study of propranolol and cyproheptadine in migraine prophylaxis. Neurol. India (2000) 48(3):223-226.
46. TFELT-HANSEN P, SAXENA P: Antiserotonin drugs. In: The Headaches. Olesen J, Tfelt-Hansen P, Welch K (Ed.), Raven Press, New York (1993):373-382.
47. BUZZI MG, MOSKOWITZ MA, PEROUTKA SJ, BYUN B: Further characterization of the putative 5-HT receptor which mediates blockade of neurogenic plasma extravasation in rat dura mater. Br. J. Pharmacol. (1991) 103(2):1421-1428.
48. ROMPEL H, BAUERMEISTER PW: Aetiology of migraine and prevention with carbamazepine (Tegretol): results of a double-blind, cross-over study. S. Afr. Med. J. (1970) 44(4):75-80.
49. HERING R, KURITZKY A: Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia (1992) 12(2):81-84.
50. JENSEN R, BRINCK T, OLESEN J: Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. Neurology (1994) 44(4):647-651.
51. MATHEW NT, SAPER JR, SILBERSTEIN SD et al.: Migraine prophylaxis with divalproex. Arch. Neurol. (1995) 52(3):281-286.
52. NAU H: Valproic acid-induced neural tube defects. Ciba Found. Symp. (1994) 181:144-152.
53. WESSELY P, BAUMGARTNER C, KLINGLER D et al.: Preliminary results of a double blind study with the new migraine prophylactic drug gabapentin. Cephalalgia (1987) 7(Suppl 6):476-477.
54. MATHEW N, LUCKER C: Gabapentin in migraine prophylaxis: A preliminary open label study. Neurology (1996) 46(Suppl. 2):A169.
55. MATHEW NT, RAPOPORT A, SAPER J et al.: Efficacy of gabapentin in migraine prophylaxis. Headache (2001) 41(2):119-128.
56. SCHOONMAN GG, WIENDELS NJ, FERRARI MD: Gabapentin in migraine prophylaxis: is it effective and well tolerated? Headache (2002) 42(3):235.
57. YOUNG WB, HOPKINS MM, SHECHTER AL, SILBERSTEIN SD: Topiramate: a case series study in migraine prophylaxis. Cephalalgia (2002) 22(8):659-663.
58. EDWARDS KR, POTTER DL, WU SC, KAMIN M, HULIHAN J: Topiramate in the preventive treatment of episodic migraine: a combined analysis from pilot, double-blind, placebo-controlled trials. CNS Spectr. (2003) 8(6):428-432.
59. STOREY JR, CALDER CS, HART DE, POTTER DL: Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache (2001) 41(10):968-975.
60. BRAY GA, HOLLANDER P, KLEIN S et al.: A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes. Res. (2003) 11(6):722-733.
61. PIJL H, MEINDERS AE: Bodyweight change as an adverse effect of drug treatment. Mechanisms and management. Drug Saf. (1996) 14(5):329-342.
62. BIGAL ME, RAPOPORT AM, SHEFTELL FD, TEPPER SJ: New migraine preventive options: an update with pathophysiological considerations. Rev. Hosp. Clin. Fac. Med. Sao Paulo (2002) 57(6):293-298.
63. CUTRER FM, LIMMROTH V, MOSKOWITZ MA: Possible mechanisms of valproate in migraine prophylaxis. Cephalalgia (1997) 17(2):93-100.
64. MCLEAN MJ, MACDONALD RL: Sodium valproate, but not ethosuximide, produces use- and voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture. J. Pharmacol. Exp. Ther. (1986) 237(3):1001-1011.
65. GOA KL, SORKIN EM: Gabapentin. A review of its pharmacological properties and clinical potential in epilepsy. Drugs (1993) 46(3):409-427.
66. HONMOU O, KOCSIS JD, RICHERSON GB: Gabapentin potentiates the conductance increase induced by nipecotic acid in CA1 pyramidal neurons in vitro. Epilepsy Res. (1995) 20(3):193-202.
67. GEE NS, BROWN JP, DISSANAYAKE VU et al.: The novel anticonvulsant drug, gabapentin (Neurontin), binds to the α2δ subunit of a calcium channel. J. Biol. Chem. (1996) 271(10):5768-5776.
68. WHITE HS: Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs. Epilepsia (1999) 40(Suppl. 5):S2-S10.
69. DODGSON SJ, SHANK RP, MARYANOFF BE: Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia (2000) 41(Suppl. 1):S35-S39.
70. ANTHONY M, LANCE JW: Monoamine oxidase inhibition in the treatment of migraine. Arch. Neurol. (1969) 21(3):263-268.
71. HENINGER G, CHARNEY D: Mechanism of action of antidepressant treatments: implications for the etiology and treatment of depressive disorders. In: Psychopharmacology: The Third Generation of Progress. Meltzer H (Ed.), Raven Press, New York (1987):535-544.
72. 1-like agonists in the treatment of migraine. J. Neurol. (1991) 238(Suppl. 1):S57-S61. A review summarising the possible role of 5-HT receptor-induced vasoconstriction in migraine therapy.
73. MOSKOWITZ MA: Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol. Sci. (1992) 13(8):307-311. A review suggesting that migraine pain results from activation of trigemino-vascular nerves.
74. 1B/D receptors in the treatment of migraine. CNS Spectrums (1998) 3:30-39.
75. 1F receptor agonists in human and bovine cerebral arteries: similarity with human coronary artery. Br J. Pharmacol. (2000) 129(3):501-508.
76. BOUCHELET I, COHEN Z, CASE B, SEGUELA P, HAMEL E: Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels. Mol. Pharmacol. (1996) 50(2):219-223.
77. 1B receptors. Mol. Pharmacol. (1996) 49(5):761-765. A basic research paper which postulates the presence of a novel target for acute antimigraine drugs (has not been supported by clinical trials).
78. 1D receptor agonist, on electrically induced dural plasma extravasation and capsaicin-evoked c-fos immunoreactivity within trigeminal nucleus caudalis. Neuropharmacology (1999) 38(7):1043-1053.
79. DIENER HC, TFELT-HANSEN P, DE BEUKELAAR F et al.: The efficacy and safety of sc alniditan versus sc sumatriptan in the acute treatment of migraine: a randomized, double-blind, placebo-controlled trial. Cephalalgia (2001) 21(6):672-679.
80. 1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs. Neuroreport (1997) 8(9-10):2237-2240.
81. BUZZI MG, CARTER WB, SHIMIZU T, HEATH H 3RD, MOSKOWITZ MA: Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion. Neuropharmacology (1991) 30(11):1193-1200.
82. 1 receptors in the therapeutic effect of triptans.
83. 1D receptor mRNA differential co-localization with peptide mRNA in the guinea pig trigeminal ganglion. Neuroreport (1998) 9(4):641-645.
84. 1B/1D/1F receptors and glutamate in trigeminal ganglia in rats. Neuroreport (2001) 12(8):1589-1591.
85. 1B/1D receptors and substance P in trigeminal ganglion neurons in rats. Eur. J. Neurosci. (2001) 13(11):2099-2104.
86. BURSTEIN R: Deconstructing migraine headache into peripheral and central sensitization. Pain (2001) 89(2-3):107-110. An analysis of the role of sensitisation in migraine headache and therapy.
87. CADY RK, SHEFTELL F, LIPTON RB et al.: Effect of early intervention with sumatriptan on migraine pain: retrospective analyses of data from three clinical trials. Clin. Ther. (2000) 22(9):1035-1048.
88. HALPERN MT, LIPTON RB, CADY RK et al.: Costs and outcomes of early versus delayed migraine treatment with sumatriptan. Headache (2002) 42(10):984-999.
89. HU XH, RASKIN NH, COWAN R, MARKSON LE, BERGER ML: Treatment of migraine with rizatriptan: when to take the medication. Headache (2002) 42(1):16-20.
90. PASCUAL J, CABARROCAS X: Within-patient early versus delayed treatment of migraine attacks with almotriptan: the sooner the better. Headache (2002) 42(1):28-31.
91. BURSTEIN R, YAMAMURA H, MALICK A, STRASSMAN AM: Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons. J. Neurophysiol. (1998) 79(2):964-982.
92. RANDIC M, JIANG MC, CERNE R: Long-term potentiation and long-term depression of primary afferent neurotransmission in the rat spinal cord. J. Neurosci. (1993) 13(12):5228-5241.
93. YU XM, ASKALAN R, KEIL GJ 2ND, SALTER MW: NMDA channel regulation by channel-associated protein tyrosine kinase Src. Science (1997) 275(5300):674-678.
94. LI P, KERCHNER GA, SALA C et al.: AMPA receptor-PDZ interactions in facilitation of spinal sensory synapses. Nat. Neurosci. (1999) 2(11):972-977.
95. DIAZ A, DICKENSON AH: Blockade of spinal N- and P-type, but not L-type, calcium channels inhibits the excitability of rat dorsal horn neurones produced by subcutaneous formalin inflammation. Pain (1997) 69(1-2):93-100.
96. FIELD MJ, OLES RJ, LEWIS AS et al.: Gabapentin (neurontin) and S-(+)-3-isobutylgaba represent a novel class of selective antihyperalgesic agents. Br. J. Pharmacol. (1997) 121(8):1513-1522.
97. DI TRAPANI G, MEI D, MARRA C, MAZZA S, CAPUANO A: Gabapentin in the prophylaxis of migraine: a double-blind randomized placebo-controlled study. Clin. Ther. (2000) 151(3):145-148.
98. HU B, CHIANG CY, HU JW, DOSTROVSKY JO, SESSLE BJ: P2X receptors in trigeminal subnucleus caudalis modulate central sensitization in trigeminal subnucleus oralis. J. Neurophysiol. (2002) 88(4):1614-1624.
99. WOOLF CJ, SALTER MW: Neuronal plasticity: increasing the gain in pain. Science (2000) 288(5472):1765-1769. An excellent review on the mechanisms of nociceptive sensitisation.
100. AKOPIAN AN, SOUSLOVA V, ENGLAND S et al.: The tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathways. Nat. Neurosci. (1999) 2(6):541-548.
101. CHEN CC, AKOPIAN AN, SIVILOTII L et al.: A P2X purinoceptor expressed by a subset of sensory neurons. Nature (1995) 377(6548):428-431.
102. WOLFF H: The cerebral circulation. Arch. Neurol. Psychiatr (1929) 22:686-699.
103. OLESEN J, IVERSEN HK, THOMSEN LL: Nitric oxide supersensitivity: a possible molecular mechanism of migraine pain. Neuroreport (1993) 4(8):1027-1030.
104. LASSEN LH, ASHINA M, CHRISTIANSEN I et al.: Nitric oxide synthase inhibition: a new principle in the treatment of migraine attacks. Cephalalgia (1998) 18(1):27-32.
105. STEPIEN A, CHALIMONIUK M: Level of nitric oxide-dependent cGMP in patients with migraine. Cephalalgia (1998) 18(9):631-634.
106. SHIMOMURA T, MURAKAMI F, KOTANI K, IKAWA S, KONO S: Platelet nitric oxide metabolites in migraine. Cephalalgia (1999) 19(4):218-222.
107. LEONE M, ATTANASIO A, CROCI D et al.: The serotonergic agent m-chlorophenylpiperazine induces migraine attacks: A controlled study. Neurology (2000) 55(1):136-139.
108. LUO ZD, CIZKOVA D: The role of nitric oxide in nociception. Curr. Rev. Pain (2000) 4(6):459-466.
109. READ SJ, MANNING P, MCNEIL CJ, HUNTER AJ, PARSONS AA: Effects of sumatriptan on nitric oxide and superoxide balance during glyceryl trinitrate infusion in the rat. Implications for antimigraine mechanisms. Brain Res. (1999) 847(1):1-8.
110. TASSORELLI C, JOSEPH SA: NADPH-diaphorase activity and Fos expression in brain nuclei following nitroglycerin administration. Brain Res. (1995) 695(1):37-44.
111. BATTELLI L, BLACK KR, WRAY SH: Transcranial magnetic stimulation of visual area V5 in migraine. Neurology (2002) 58(7):1066-1069.
112. SOMJEN GG: Mechanisms of spreading depression and hypoxic spreading depression-like depolarization. Physiol. Rev. (2001) 81(3):1065-1096.
113. INGVARDSEN BK, LAURSEN H, OLSEN UB, HANSEN AJ: Possible mechanism of c-fos expression in trigeminal nucleus caudalis following cortical spreading depression. Pain (1997) 72(3):407-415.
114. EBERSBERGER A, SCHAIBLE HG, AVERBECK B, RICHTER F: Is there a correlation between spreading depression, neurogenic inflammation, and noriception that might cause migraine headache? Ann. Neurol. (2001) 49(1):7-13.
115. GOADSBY PJ: Migraine, aura, and cortical spreading depression: why are we still talking about it? Ann. Neurol. (2001) 49(1):4-6. A contrasting view on the role of CSD in migraine pathogenesis.
116. HADJIKHANI N, SANCHEZ DEL RIO M, WU O et al.: Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc. Natl. Acad. Sci. USA (2001) 98(8):4687-4692.
117. CAO Y, WELCH KM, AURORA S, VIKINGSTAD EM: Functional MRI-BOLD of visually triggered headache in patients with migraine. Arch. Neurol. (1999) 56(5):548-554.
118. MOSKOWITZ MA, NOZAKI K, KRAIG RP: Neocortical spreading depression provokes the expression of c-fos protein-like immunoreactivity within trigeminal nucleus caudalis via trigeminovascular mechanisms. J. Neurosci. (1993) 13(3):1167-1177.
119. BOLAY H, REUTER U, DUNN AK et al.: Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat. Med. (2002) 8(2):136-142. Animal study exploring the link between cortical neuron activity and the activation of the trigemino-vascular system.
120. JING J, AITKEN PG, SOMJEN GG: Role of calcium channels in spreading depression in rat hippocampal slices. Brain Res. (1993) 604(1-2):251-259.
121. RICHTER F, EBERSBERGER A, SCHAIBLE HG: Blockade of voltage-gated calcium channels in rat inhibits repetitive cortical spreading depression. Neurosci. Lett. (2002) 334(2):123-126.
122. AYATA C, SHIMIZU-SASAMATA M, LO EH, NOEBELS JL, MOSKOWITZ MA: Impaired neurotransmitter release and elevated threshold for cortical spreading depression in mice with mutations in the alpha1A subunit of PIQ type calcium channels. Neuroscience (2000) 95(3):639-645.
123. WESTENBROEK RE, SAKURAI T, ELLIOTT EM et al.: Immunochemical identification and subcellular distribution of the alpha 1A subunits of brain calcium channels. J. Neurosci. (1995) 15(10):6403-6418.
124. 2+ channels in mammalian central neurons. Trends Neurosci. (1995) 18(2):89-98.
125. OPHOFF RA, TERWINDT GM, VERGOUWE MN et al.: Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell (1996) 87(3):543-552. First established link between a gene defect and a subtype of migraine.
126. V21 current density in neurons. Proc. Natl. Acad. Sci. USA (2002) 99(20):13284-13289. This study examines the physiological connection between the gene defect in FHM and the human disease.
127. tg) mouse thalami. J. Neurophysiol. (1999) 81(5):2066-2074,
128. TERWINDT GM, OPHOFF RA, VAN EIJK R et al.: Involvement of the CACNA1A gene containing region on 19p13 in migraine with and without aura. Neurology (2001) 56(8):1028-1032.
129. 1B/1D receptors in models relevant to migraine. J. Pharmacol. Exp. Ther. (1999) 290(1):83-95.
130. DUKAT M: Donitriptan (Pierre Fabre). Curr. Opin. Investig. Drugs (2001) 2(3):415-418.
131. 1B/1D) agonists in a model of trigeminovascular nociception in cat. Exp. Neurol. (1998) 150(1):45-51.
132. DINGEMANSE J, SOUBROUILLARD C, PARIS J, PISANO P, BLIN O: Pronounced effect of caprylocaproyl macrogolglycerides on nasal absorption of IS-159, a peptide serotonin 1B/1D-receptor agonist. Clin. Pharmacol. Ther. (2000) 68(2):114-121.
133. KRYMCHANTOWSKI AV, ADRIANO M, FERNANDES D: Tolfenamic acid decreases migraine recurrence when used with sumatriptan. Cephalalgia (1999) 19(3):186-187.
134. KRYMCHANTOWSKI AV, BARBOSA JS: Rizatriptan combined with rofecoxib versus rizatriptan for the acute treatment of migraine: an open label pilot study. Cephalalgia (2002) 22(4):309-312.
135. DIMITRIADOU V, BUZZI MG, THEOHARIDES TC, MOSKOWITZ MA: Ultrastrucrural evidence for neurogenically mediated changes in blood vessels of the rat dura mater and tongue following antidromic trigeminal stimulation. Neuroscience (1992) 48(1):187-203.
136. DIMITRIADOU V, BUZZI MG, MOSKOWITZ MA, THEOHARIDES TC: Trigeminal sensory fiber stimulation induces morphological changes reflecting secretion in rat dura mater mast cells. Neuroscience (1991) 44(1):97-112.
137. GOADSBY PJ, EDVINSSON L, EKMAN R: Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann. Neurol. (1988) 23(2):193-196.
138. GOADSBY PJ, EDVINSSON L, EKMAN R: Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann. Neurol. (1990) 28(2):183-187. This study shows that CGRP is released during migraine attacks, pointing to CGRP receptors as a potential drug target.
139. GOADSBY PJ, EDVINSSON L: The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann. Neurol. (1993) 33(1):48-56.
140. SUN RQ, LAWAND NB, WILLIS WD: The role of calcitonin gene-related peptide (CGRP) in the generation and maintenance of mechanical allodynia and hyperalgesia in rats after intradermal injection of capsaicin. Pain (2003) 104(1-2):201-208.
141. LASSEN LH, HADERSLEV PA, JACOBSEN VB et al.: CGRP may play a causative role in migraine. Cephalalgia (2002) 22(1):54-61.
142. WU D, DOODS H, ARNDT K, SCHINDLER M: Development and potential of non-peptide antagonists for calcitonin-gene-related peptide (CGRP) receptors: evidence for CGRP receptor heterogeneity. Biochem. Soc. Trans. (2002) 30(4):468-473.
143. DOODS H, HALLERMAYER G, WU D et al.: Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br. J. Pharmacol. (2000) 129(3):420-423.
144. MORENO MJ, ABOUNADER R, HEBERT E, DOODS H, HAMEL E: Efficacy of the non-peptide CGRP receptor antagonist BIBN4096BS in blocking CGRP-induced dilations in human and bovine cerebral arteries: potential implications in acute migraine treatment. Neuropharmacology (2002) 42(4):568-576.
145. EDVINSSON L: New therapeutic target in primary headaches - blocking the CGRP receptor. Expert Opin. Ther. Targets (2003) 7(3):377-383.
146. HOVINGA CA: Novel anticonvulsant medications in development. Expert Opin. Investig. Drugs (2002) 11(10):1387-1406.
147. MAASSENVANDENBRINK A, VAN DEN BROEK RW, DE VRIES R et al.: The potential anti-migraine compound SB-220453 does not contract human isolated blood vessels or myocardium; a comparison with sumatriptan. Cephalalgia (2000) 20(6):538-545.
148. SMITH MI, READ SJ, CHAN WN et al.: Repetitive cortical spreading depression in a gyrencephalic feline brain: inhibition by the novel benzoylamino-benzopyran SB-220453. Cephalalgia (2000) 20(6):546-553. Animal experiments documenting a novel mechanism of action for a potential antimigraine drug.
149. BRADLEY DP, SMITH MI, NETSIRI C et al.: Diffusion-weighted MRI used to detect in vivo modulation of cortical spreading depression: comparison of sumatriptan and tonabersat. Exp. Neurol. (2001) 172(2):342-353.
150. KAUBE H, GOADSBY PJ: Anti-migraine compounds fail to modulate the propagation of cortical spreading depression in the cat. Eur. Neurol. (1994) 34(1):30-35.
151. PARSONS AA, BINGHAM S, RAVAL P et al.: Tonabersat (SB-220453) a novel benzopyran with anticonvulsant properties attenuates trigeminal nerve-induced neurovascular reflexes. Br. J. Pharmacol. (2001) 132(7):1549-1557.
152. ISOHERRANEN N, YAGEN B, BIALER M: New CNS-active drugs which are second-generation valproic acid: can they lead to the development of a magic bullet? Curr. Opin. Neurol. (2003) 16(2):203-211.
153. BIALER M: Valrocemide. Sixth Eilat Conference on New Antiepileptic Drugs (2002):AB36.
154. LAURITZEN M, HANSEN AJ, KRONBORG D, WIELOCH T: Cortical spreading depression is associated with arachidonic acid accumulation and preservation of energy charge. J. Cereb. Blood Flow Metab. (1990) 10(1):115-122.
155. NAKANO T, OHARA O, TERAOKA H, ARITA H: Group II phospholipase A2 mRNA synthesis is stimulated by two distinct mechanisms in rat vascular smooth muscle cells. FEBS Lett. (1990) 261(1):171-174.
156. OKA S, ARITA H: Inflammatory factors stimulate expression of group II phospholipase A2 in rat cultured astrocytes. Two distinct pathways of the gene expression. J. Biol. Chem. (1991) 266(15):9956-9960.
157. ARBIBE L, VIAL D, ROSINSKI-CHUPIN I et al.: Endotoxin induces expression of Type II phospholipase A2 in macrophages during acute lung injury in guinea pigs: involvement of TNF-alpha in lipopolysaccharide-induced type II phospholipase A2 synthesis. J. Immunol. (1997) 159(1):391-400.
158. VERVOORDELDONK MJ, PINEDA TORRA IM, AARSMAN AJ, VAN DEN BOSCH H: Aspirin inhibits expression of the interleukin-1β-inducible group II phospholipase A2. FEBS Lett. (1996) 397(1):108-112.
159. KUWATA H, NAKATANI Y, MURAKAMI M, KUDO I: Cytosolic phospholipase A2 is required for cytokine-induced expression of type IIA secretory phospholipase A2 that mediates optimal cydooxygenase-2-dependent delayed prostaglandin E2 generation in rat 3Y1 fibroblasts. J. Biol. Chem. (1998) 273(3):1733-1740.
160. MORIOKA N, TAKEDA K, KUMAGAI K et al.: Interleukin-1β-induced substance P release from rat cultured primary afferent neurons driven by two phospholipase A2 enzymes: secretory type IIA and cytosolic type IV. J. Neurochem. (2002) 80(6):989-997.
161. KRAMER RM, HESSION C, JOHANSEN B et al.: Structure and properties of a human non-pancreatic phospholipase A2. J. Biol. Chem. (1989) 264(10):5768-5775.
162. 2/prostaglandin endoperoxide receptor antagonist. J. Cardiovasc. Pharmacol. (1993) 21(3):441-447.
163. GE ZD, AUCHAMPACH JA, PIPER GM, GROSS GJ: Comparison of cardioprotective efficacy of two thromboxane A2 receptor antagonists. J. Cardiovasc. Pharmacol. (2003) 41(3):481-488.
164. HANINGTON E, JONES RJ, AMESS JA, WACHOWICZ B: Migraine: a platelet disorder. Lancet (1981) 2(8249):720-723.
165. KITANO A, SHIMOMURA T, TAKESHIMA T, TAKAHASHI K: Increased 11-dehydrothromboxane B2 in migraine: platelet hyperfunction in patients with migraine during headache-free period. Headache (1994) 34(9):515-518.
166. REUTER U, CHIARUGI A, BOLAY H, MOSKOWITZ MA: Nuclear factor-kappaB as a molecular target for migraine therapy Ann. Neurol. (2002) 51(4):507-516.
167. VAN DER KUY PH, MERKUS FW, LOHMAN JJ, TER BERG JW, HOOYMANS PM: Hydroxocobalamin, a nitric oxide scavenger, in the prophylaxis of migraine: an open, pilot study. Cephalalgia (2002) 22(7):513-519.
168. READ SJ, PARSONS AA: Sumatriptan modifies cortical free radical release during cortical spreading depression. A novel antimigraine action for sumatriptan? Brain Res. (2000) 870(1-2):44-53.
169. STEWART WF, LIPTON RB, CELENTANO DD, REED ML: Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA (1992) 267(1):64-69.
170. LIPTON RB, DIAMOND S, REED M, DIAMOND ML, STEWART WF: Migraine diagnosis and treatment: results from the American Migraine Study II. Headache (2001) 41(7):638-645.
171. NATTERO G: Menstrual headache. Adv. Neurol. (1982) 33(215-226.
172. SOMERVILLE BW: Estrogen-withdrawal migraine. I. Duration of exposure required and attempted prophylaxis by premenstrual estrogen administration. Neurology (1975) 25(3):239-244.
173. HAYASHI T, FUKUTO JM, IGNARRO LJ, CHAUDHURI G: Basal release of nitric oxide from aortic rings is greater in female rabbits than in male rabbits: implications for atherosclerosis. Proc. Natl. Acad. Sci. USA (1992) 89(23):11259-11263.
174. WEINER CP, LIZASOAIN I, BAYLIS SA et al.: Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc. Natl. Acad. Sci. USA (1994) 91(11):5212-5216.
175. 2+ release induced by thromboxane A2 in porcine coronary artery. Circulation (1995) 91(10):2619-2626.
176. KITAZAWA T, HAMADA E, KITAZAWA K, GAZNABI AK: Non-genomic mechanism of 17 beta-oestradiol-induced inhibition of contraction in mammalian vascular smooth muscle. J. Physiol. (1997) 499(Pt 2):497-511.
177. HARDER DR, COULSON PB: Estrogen receptors and effects of estrogen on membrane electrical properties of coronary vascular smooth muscle. J. Cell. Physiol. (1979) 100(2):375-382.
178. Ca channels through a cGMP-dependent mechanism. Circ. Res. (1995) 77(5):936-942.
179. GEARY GG, KRAUSE DN, DUCKLES SP: Estrogen reduces myogenic tone through a nitric oxide-dependent mechanism in rat cerebral arteries. Am. J. Physiol. (1998) 275(1 Pt 2):H292-300.
180. GEARY GG, KRAUSE DN, DUCKLES SP: Estrogen reduces mouse cerebral artery tone through endothelial NOS- and cyclooxygenase-dependent mechanisms. Am. J.
181. KELLY MJ, QIU J, WAGNER EJ, RONNEKLEIV OK: Rapid effects of estrogen on G protein-coupled receptor activation of potassium channels in the central nervous system (CNS). J. Steroid Biochem. Mol. Biol. (2002) 83(1-5):187-193.
182. KELLY MJ, RONNEKLEIV OK, ESKAY RL: Identification of estrogen-responsive LHRH neurons in the guinea pig hypothalamus. Brain Res. Bull (1984) 12(4):399-407.
183. LAGRANGE AH, RONNEKLEIV OK, KELLY MJ: Estradiol-17 beta and mu-opioid peptides rapidly hyperpolarize GnRH neurons: a cellular mechanism of negative feedback? Endocrinology (1995) 136(5):2341-2344.
184. + channel (SK3) mRNA in the guinea pig brain. Endocrinology (2002) 143(3):1097-1107.
185. WONG M, THOMPSON TL, MOSS RL: Nongenomic actions of estrogen in the brain: physiological significance and cellular mechanisms. Crit. Rev. Neurobiol. (1996) 10(2):189-203.
186. WOOLLEY CS, WEILAND NG, MCEWEN BS, SCHWARTZKROIN PA: Estradiol increases the sensitivity of hippocampal CA1 pyramidal cells to NMDA receptor-mediated synaptic input: correlation with dendritic spine density. J. Neurosci. (1997) 17(5):1848-1859.
187. WOOLLEY CS: Electrophysiological and cellular effects of estrogen on neuronal function. Crit. Rev. Neurobiol. (1999) 13(1):1-20.
188. WOOLLEY CS, SCHWARTZKROIN PA: Hormonal effects on the brain. Epilepsia (1998) 39(Suppl. 8):S2-S8.
189. ZURAK N: Role of the suprachiasmatic nucleus in the pathogenesis of migraine attacks. Cephalalgia (1997) 17(7):723-728.
190. FACCHINETTI F, SGARBI L, PICCININI F: Hypothalamic resetting at puberty and the sexual dimorphism of migraine. Funct. Neurol. (2000) 15(Suppl. 3):137-142.
191. MAIZELS M, SCOTT B, COHEN W, CHEN W: Intranasal lidocaine for treatment of migraine: a randomized, double-blind, controlled trial. JAMA (1996) 276(4):319-321.
192. MEI J, PASTERNAK GW: Sigma1 receptor modulation of opioid analgesia in the mouse. J. Pharmacol. Exp. Ther. (2002) 300(3):1070-1074.
193. WEINBROUM AA, RUDICK V, PARET G, BEN-ABRAHAM R: The role of dextromethorphan in pain control. Can. J. Anaesth. (2000) 47(6):585-596.
194. ANDERSON TR, ANDREW RD: Spreading depression: imaging and blockade in the rat neocortical brain slice. J. Neurophysiol. (2002) 88(5):2713-2725.
195. CRUICKSHANK JM: The clinical importance of cardioselectivity and lipophilicity in beta blockers. Am. Heart J. (1980) 100(2):160-178.
196. ROSEN JA: Observations on the efficacy of propranolol for the prophylaxis of migraine. Ann. Neurol. (1983) 13(1):92-93.
197. LODER E, BIONDI D: Use of botulinum toxins for chronic headaches: a focused review. Clin. J. Pain (2002) 18(6 Suppl.):S169-S176.
198. GARDNER K: The genetic basis of migraine: how much do we know? Can. J. Neurol. Sci. (1999) 26(Suppl. 3):S37-S43.